このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

FluoGuide マネジメント

マネジメント基準チェック /14

FluoGuide'sの CEO はMorten Albrechtsenで、 Jan2018年に任命され、の在任期間は 6.42年です。は、会社の株式の12.19%を直接所有しており、その価値はSEK 68.68M 。経営陣と取締役会の平均在任期間はそれぞれ4.9年と2.1年です。

主要情報

Morten Albrechtsen

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	6.4yrs
CEOの所有権	12.2%
経営陣の平均在職期間	4.9yrs
取締役会の平均在任期間	2.1yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Morten Albrechtsen (60 yo)

6.4yrs

在職期間

Mr. Morten Albrechtsen, M.D., BBA, has been the CEO at Fluoguide A/s since 2018. He is the Co-founder and serves as the Chief Executive Officer at radiotherapy specialists Nanovi ApS. Mr. Albrechtsen Found...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Morten Albrechtsen	Chief Executive Officer	6.4yrs	データなし	12.19% DKK 70.3m
Ole Larsen	Chief Financial Officer	1.3yrs	データなし	データなし
Andreas Kjaer	CSO, CMO	no data	データなし	17.42% DKK 100.5m
Grethe Rasmussen	Chief Development Officer	5.4yrs	データなし	データなし
Dorthe Mejer	Vice President of Clinical Development	4.4yrs	データなし	データなし

4.9yrs

平均在職期間

60.5yo

平均年齢

経験豊富な経営陣: FLUOの経営陣は経験豊富であると考えられます ( 4.9年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Andreas Kjaer	CSO, CMO	6.4yrs	データなし	17.42% DKK 100.5m
Mats Thoren	Vice Chairman of the Board	3yrs	データなし	データなし
Donna Haire	Director	less than a year	データなし	データなし
Peter Eriksen	Independent Chairman	5.4yrs	データなし	データなし
Michael Engsig	Independent Director	1.3yrs	データなし	データなし
Roger Gunnarsson	Director	less than a year	データなし	データなし

2.1yrs

平均在職期間

55yo

平均年齢

経験豊富なボード: FLUOの取締役会は経験豊富ではない ( 2.1年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

FluoGuide マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Less than half of directors are independent

Less than half of directors are independent

FluoGuide A/S Approves Board Changes

FluoGuide A/S Appoints Ole Larsen as Chief Financial Officer

FluoGuide A/S, Annual General Meeting, Mar 21, 2023

FluoGuide Announces CFO Changes

Recent updates

FluoGuide A/S to Report Fiscal Year 2024 Final Results on Feb 27, 2025

Less than half of directors are independent

Less than half of directors are independent

FluoGuide A/S Approves Board Changes

New major risk - Revenue and earnings growth

No longer forecast to breakeven

FluoGuide A/S to Report Q2, 2024 Results on Aug 29, 2024

New minor risk - Share price stability

FluoGuide A/S Provides Strategic Update and Outlines Development Plans Towards Commercialization of FG001

New minor risk - Shareholder dilution

FluoGuide A/S Announces FG001 Meets Primary Endpoint in Phase LLB Trial in Aggressive Brain Cancer

FluoGuide A/S Confirms Positive Topline Results from Phase IIa Trial of FG001 in Head & Neck Cancer at International Academy of Oral Oncology Conference

Pfluoguide A/S Provides Positive Interim Data from Phase Lla Trial of Fg001 in Head & Neck Cancer Presented as A Case Report At the World Molecular Imaging Congress in Prague

New minor risk - Profitability

Fluoguide A/S Announces Completion of Patient Enrollment and Treatment in the Phase IIb Trial with Fg001 in Patients with Aggressive Brain Cancer

FluoGuide A/S Announces Positive Interim Results from Phase IIa Trial of FG001 in Head & Neck Cancer

Fluoguide A/S Announces Positive Topline Results from Phase Iia Trial of Fg001 in Lung Cancer

FluoGuide A/S to Report Q3, 2023 Results on Nov 29, 2023

FluoGuide A/S Appoints Ole Larsen as Chief Financial Officer

Companies Like FluoGuide (STO:FLUO) Are In A Position To Invest In Growth

FluoGuide A/S Releases Positive Interim Result of FG001 in Head and Neck Cancer

FluoGuide A/S, Annual General Meeting, Mar 21, 2023

FluoGuide A/S to Report Fiscal Year 2022 Results on Feb 28, 2023

FluoGuide A/S Enrolls First Patient in the Phase IIa Trial in Head and Neck Cancer

FluoGuide A/S Reaches Milestone with FG001 for Phase III Clinical Supply

FluoGuide A/S Releases Positive Interim Result of FG001-CT002

FluoGuide A/S Enrolls the First Patient in the Phase IIb Trial in Aggressive Brain Cancer

FluoGuide (STO:FLUO) Is In A Good Position To Deliver On Growth Plans

FluoGuide A/S Presents the Outstanding Clinical Data from the Completed Phase I/IIa Trial with FG001 in Patients with Aggressive Brain Cancer Undergoing Surgery, At the World Molecular Imaging Congress

FluoGuide A/S Ordinary Shares to Be Deleted from OTC Equity

FluoGuide A/S Receives Approval from the Danish Medicines Agency to Initiate Phase Ii Trial with Fg001 in Head and Neck Cancer

FluoGuide Announces CFO Changes

FluoGuide Receives Permission to Start Phase IIb Trial in Aggressive Brain Cancer

Fluoguide A/S Update on Fg001's Clinical Development

FluoGuide Submits a Clinical Trial Application (CTA) to the Danish Medicines Agency to Initiate Phase II Trial with FG001 in Head and Neck Cancer

FluoGuide Publish the Presentation of FG001 Results from the First Clinical Trial in Aggressive Brain Cancer

We're Hopeful That FluoGuide (STO:FLUO) Will Use Its Cash Wisely

FluoGuide A/S Announces Positive Top Line Result from Ongoing Clinical Phase I/II Trial

FluoGuide (STO:FLUO) Is In A Good Position To Deliver On Growth Plans

FluoGuide Submits Clinical Trial Application to the Danish Medicines Agency to Initiate Phase Ii Trial with Fg001 in Lung Cancer

Fluoguide Proceeds to Seventh Dose Level with Fg001 in the Ongoing Clinical Phase I/II Trial Following Continued Improvement of Tumor Illumination with Increasing Doses

FluoGuide Announces Regulatory Approval from Swedish Authorities to Commence Phase II Clinical Trial with FG001 in Guiding Surgery of High Grade Glioma in Sweden

FluoGuide A/S Announces Publication of Promising Preclinical Data on FG001 Effect in Treatment of Cancer

FluoGuide A/S Announces Promising Preclinical Data with Fg002 Technology in Guiding Surgical Removal of Cancer

FluoGuide has Received Green Light to Proceed to the Next Dose Level with FG001 in the Ongoing Clinical Phase I/II Trial in Patients Undergoing Surgical Treatment of High Grade Glioma

FluoGuide Receives Approval to Commence with FG001 in Evening Dosing in the Ongoing Clinical Phase I/II Trial in Patients with High Grade Glioma

FluoGuide A/S Acquires Rights to Photothermal Therapy Using FG001

Companies Like FluoGuide (STO:FLUO) Are In A Position To Invest In Growth

Dose Escalation Committee Approves FluoGuide A/S's Initiation of the Fourth Dose Level in the Ongoing Clinical Phase I/II Trial Evaluating Safety and Efficacy of Fg001 in Patients with High Grade Glioma Undergoing Neurosurgery

Chairman Arne Ferstad has left the company

Fluoguide A/S Announces Management Changes At the Annual General Meeting Held on February 9, 2021

Fluoguide A/S Announces Publication of Two Patent Applications Covering the Company's uPAR Technology Platform for Improving Surgery

FluoGuide A/S to Report Nine Months, 2021 Results on Nov 24, 2021

New 90-day high: kr.132

FluoGuide A/S Gets Green Light to Proceed to Second Dose Level with FG001 in the Ongoing Clinical Phase I/II Trial in Patients with High Grade Glioma

New 90-day low: kr.46.20

FluoGuide A/S Announces First Patient Enrolled in the Phase I/II Clinical Trial Testing FG001 in Patients with High Grade Glioma

FluoGuide Appoints Henrik Moltke as Chief Financial Officer, Effective December 2020

New 90-day high - kr.40.00

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /14